The National Institute for Health and Care Research has awarded funding to 19 projects intended to place preventive health technologies inside community services rather than leaving them in stand-alone trials or hospital settings. The new awards range from £50,000 to £100,000 per project for up to one year and are aimed at turning local adoption into a practical part of care delivery.
The funding round sits within the Invention for Innovation programme’s Funding At the Speed of Translation scheme. Its focus is not a single medical device or a national rollout. Instead, the projects will test how particular technologies can be integrated into settings where people already seek support, including community pharmacies, diagnostic centres, schools, hospices and mobile outreach services. The programme is being delivered with the HealthTech Research Centre Network.
That emphasis matters because a technology that has performed well in development still has to fit into a real consultation, referral route and record-keeping system before it can make a difference to patients. The awards are intended to address that practical stage of adoption. Each project will work with local services and is framed around prevention, earlier identification or support outside hospital.
The funded portfolio ranges across cancer, stroke rehabilitation, oral health, mental health, maternity care, asthma, diabetes, dementia, palliative care and pressure-ulcer prevention. It therefore reflects the breadth of community health care rather than a narrow technology programme. The common objective is to reach people earlier and, where possible, in places that may be easier to access than specialist services.
Several examples illustrate the approach. MpRisk is designed to help midwives identify people who may face higher risk during or after pregnancy and to connect them with local services. CanSense-CRC is a blood-test pathway for bowel-cancer detection which is to be explored as an alternative for people unable or unwilling to complete a faecal test. Its proposed delivery routes include general practice, at-home sampling and community pharmacies.
A third project, the Intelligent Clinical Assessment Platform, is designed to give advanced clinical practitioners step-by-step, evidence-based support when managing complex gynaecological conditions in GP surgeries. The project is intended to improve earlier recognition and referral, an issue the programme identifies as particularly important in deprived communities. Other awards cover remote foot monitoring in community podiatry, rapid asthma screening through pharmacies, a school-based oral-health intervention and a pharmacy link spanning patient support, mental-health prevention and NHS records.
The funding should not be read as a finding that any of the 19 products is already proven to improve outcomes or ready for national commissioning. The awards support integration and feasibility work for a limited period. Each project will need to show that its technology can be used safely and usefully within the relevant local pathway, and that the service model is workable for patients and staff.
For the NHS, the programme points to a wider policy direction: moving parts of prevention and earlier detection into neighbourhood settings. That can mean bringing a test, decision-support tool or monitoring service closer to everyday care, but it does not remove the need for clinical assessment, referral or specialist treatment when those are required. The next evidence will come from the individual projects as they work with their community partners over the year ahead.
